Jaxteran (Dimethyl Fumarate)

Dimethyl fumarate activates the Nrf2 cellular pathway, which increases antioxidant defenses and reduces inflammatory signaling. This dual action modulates immune cell activity, leading to decreased neuroinflammation and protection of nerve cells in multiple sclerosis.

The specific dose and titration schedule for Jaxteran are determined by the prescribing clinician based on individual patient factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of dimethyl fumarate in pregnancy and lactation has not been established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Jaxteran.

To request Jaxteran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jaxteran (dimethyl fumarate) is an oral disease‑modifying agent that offers a convenient route of administration compared with injectable or infusion therapies. Its mechanism focuses on antioxidant and anti‑inflammatory pathways, whereas other classes such as interferons target cytokine signaling. Choice of therapy depends on efficacy, safety profile, patient preference and physician assessment.

Jaxteran should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Jaxteran is taken orally, usually as a tablet swallowed with water. The exact dosing schedule, including any titration phases, is set by the prescribing clinician. Patients should not crush or chew the tablets unless specifically instructed.

The most serious risks include severe lymphopenia, which can increase susceptibility to infections, and the rare occurrence of progressive multifocal leukoencephalopathy (PML), a potentially fatal brain infection. Regular monitoring of blood counts and vigilance for signs of infection are essential.

Jaxteran is contraindicated in patients with known hypersensitivity to dimethyl fumarate or any of its excipients. It should also be avoided in individuals with active infections, severe hepatic impairment, or those receiving live vaccines without appropriate medical supervision.